Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline UK and US Performance Share Plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
Key transaction details include:
- Transaction Date: April 17, 2013
- Underlying Event: Notional re-investment of the dividend paid to shareholders on April 11, 2013.
- Share Prices: Ordinary Shares at 1565.50 pence; American Depositary Shares (ADSs) at $48.52.
Material Changes
The filing details increases in notional interests in Ordinary Shares and ADSs for various executives following the dividend re-investment. No material changes to the company's financial position or operations are reported in this specific document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors to Verify
- Verify the vesting schedules and performance conditions for the UK and US Performance Share Plans to understand future payout obligations.
- Confirm the total number of shares or ADSs held by the listed executives prior to this notional increase to assess total exposure.
- Review the full dividend announcement from April 11, 2013, to understand the cash flow impact on the company.